We further analyzed scRNA-seq data from 48 biopsied melanoma tissues (32 patients in immune checkpoint blockade (ICB) clinical trials, acquired from the 3CA database [17]), including 19 pretreatment samples (nonresponders (NR), n = 10; and responders (R), n = 9) and 29 post-treatment samples (NR, n = 21, and R, n = 8) with 16,291 high-quality CD45+ cells. Here, PTPRC is linked to melanoma.